Literature DB >> 15598314

Autopsy case of prostate cancer with multiple endocrine neoplasia 2A.

Eiwa Ishida1, Mitsutoshi Nakamura, Keiji Shimada, Syuichi Matsuyoshi, Kazuhiro Tada, Eijiro Okajima, Kiyohide Fujimoto, Noboru Konishi.   

Abstract

We describe an autopsy case of a 65-year-old man with prostate cancer accompanied by multiple endocrine neoplasia 2A (MEN 2A), including malignant pheochromocytomas, thyroid medullary carcinomas and parathyroid hyperplasia. Metastatic lesions from the prostate primary were identified using immunohistochemistry for prostate specific antigen within both primary and metastatic pheochromocytomas in the liver. To investigate the affinity of prostate cancer for pheochromocytoma cells, immunohistochemistry was carried out using a number of antibodies and both tumors were positive for N-cadherin. Interestingly, pheochromocytomas, thyroid medullary carcinomas and prostate cancer were all positive for the anti-RET antibody. The immunohistochemical results suggest that the cell affinity may, in part, result from cell-cell adhesion via N-cadherin. Although prostate cancer is rarely associated with MEN, RET activation may have participated in the tumorigenesis of this case.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15598314     DOI: 10.1111/j.1440-1827.2004.01773.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  2 in total

1.  Skip metastase on the left neck lymph nodes of the prostatic adenocarcinoma with neuroendocrine differentiation and accompanying thyroid micropapillary carcinoma.

Authors:  Levent Sagnak; Hikmet Topaloglu; Osman Gucuk; Unsal Han; Hamit Ersoy
Journal:  Pathol Oncol Res       Date:  2008-04-02       Impact factor: 3.201

2.  N-cadherin dependent collective cell invasion of prostate cancer cells is regulated by the N-terminus of α-catenin.

Authors:  Yuanyuan Cui; Soichiro Yamada
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.